Customized endonuclease will be available as Denarase for biopharma applications.
Sartorius Stedim Biotech negotiated worldwide sales and distribution rights to c-LEcta’s Serratia marcescens nuclease for biopharmaceutical applications. Under terms of the deal the customized endonuclease will be available as Denarase through all Sartorius Stedim Biotech’s sales channels.
German firm c-LEcta specializes in the development of customized enzymes and production strains for industrial applications. The firm has optimized the production process for Serratia marcescens nuclease using a genetically engineered Bacillus strain to increase enzyme activity yields and remove endotoxins.
“This endonuclease provides outstanding advantages from which our customers will benefit directly, such as cost efficiency and high performance,” remarks Uwe Gottschalk, Ph.D., vp of purification technologies at Sartorius Stedim Biotech. “The nuclease is a perfect addition to our current purification product portfolio and supports our strategy as a total solution provider for the biopharmaceutical industry.”
Germany-based c-LEcta specializes in the development of customized enzymes and production strains for industrial applications. The firm applies patented technologies to enable the discovery and optimization of customized enzymes and microbial strains for the production of protein and small-molecule products. In January the firm achieved ISO 9001 certification, covering all operational areas from R&D to production and product sales.
